Sintilimab

Generic Name: Sintilimab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2072873-06-2

Unique Ingredient Identifier: 8FU7FQ8UPK

Associated Conditions: -

Associated Therapies: -

Clinical Trials

PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma

Phase 2

Conditions: Nasopharyngeal Neoplasms

Interventions: Drug: Sintilimab
Drug: Gemcitabine
Drug: Cisplatin
Radiation: intensity-modulated radiotherapy

First Posted Date: 2018-08-08

Last Posted Date: 2018-10-09

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 40

Registration Number: NCT03619824

Locations: 🇨🇳
SUN YAT-SEN UNIVERSITY cANCER CENTER, Guangzhou, Guangdong, China

Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC

Phase 3

Completed

Conditions: Lung Neoplasms

Interventions: Drug: Sintilimab
Drug: Pemetrexed
Drug: Platinum
Drug: Placebos

First Posted Date: 2018-07-31

Last Posted Date: 2023-02-27

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 397

Registration Number: NCT03607539

Locations: 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, China

Phase II Umbrella Study Directed by Next Generation Sequencing

Phase 2

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Avitinib Maleate
Drug: Afatinib
Drug: Pyrotinib Maleate
Drug: Pirotinib
Drug: Nimotuzumab
Drug: Sintilimab
Drug: Crizotinib
Drug: X-396
Drug: AZD3759
Drug: Gemcitabine
Drug: Pemetrexed
Drug: Cisplatin
Drug: Chidamide
Drug: Carboplatin

First Posted Date: 2018-07-02

Last Posted Date: 2022-12-06

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 400

Registration Number: NCT03574402

Locations: 🇨🇳
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China

A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: IBI310
Drug: Sintilimab

First Posted Date: 2018-06-06

Last Posted Date: 2023-02-28

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 53

Registration Number: NCT03545971

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma Patients

Phase 2

Completed

Conditions: Effect of Drugs

Interventions: Drug: Sintilimab

First Posted Date: 2017-07-25

Last Posted Date: 2021-01-12

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 28

Registration Number: NCT03228836

Locations: 🇨🇳
Jiangsu Provincial Hospital, Nanjing, Jiangsu, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy